|Bid||155.95 x 200|
|Ask||156.05 x 100|
|Day's Range||155.14 - 159.87|
|52 Week Range||79.78 - 167.86|
|PE Ratio (TTM)||200.75|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Should Investors Be Interested in Vertex Pharmaceuticals in 2018? In 3Q17, Vertex Pharmaceuticals (VRTX) reported non-GAAP (generally accepted accounting principals) net profits of ~$136 million, which is a YoY (year-over-year) growth of ~216.3%, driven mainly by the rapid rise in total cystic fibrosis (or CF) drug sales. The company reported non-GAAP combined SG&A (selling, general, and administrative) and R&D (research and development) expenses of ~$334 million, which is a YoY rise of 13.2%.
Vertex (VRTX) receives extension of the marketing application for Orkambi to include use in children with CF who have two copies of the F508del mutation from European Commission.
Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) released its most recent earnings update in September 2017, which signalled that losses became smaller relative to the prrior year’s level as a result of recentRead More...
Vertex Pharmaceuticals (NASDAQ: VRTX ) releases its next round of earnings Monday, Jan. 8. Here's Benzinga's essential guide to Vertex's Q4 earnings report. Earnings and Revenue Based on Vertex management ...
If you were lucky enough to own these healthcare stocks, then your returns more than tripled the S&P 500 last year.
Both Vertex and Alexion enjoy dominant positions in medical areas - cystic fibrosis (CF) for Vertex and ultra-rare disorders for Alexion - that are not very competitive.
In a note on Tuesday, Geoffrey Porges at Leerink Partners identified Vertex Pharmaceuticals (VRTX) and Alexion Pharmaceuticals (ALXN) as his top two picks among large cap biotechs in 2018, citing their continued dominance in two medical areas. Alexion is slated to move into its new headquarters in Boston’s Seaport District in mid-2018, a couple blocks from where Vertex is located. In his note, Porges said that both Vertex and Alexion are poised to thrive in what he predicts will be a tough environment for Big Pharma, characterized by “hyper-competition, pricing pressure and uncertain M&A activity.” According to Porges, that's because both companies focus on diseases — cystic fibrosis for Vertex, and a rare blood disorder in the case of Alexion — for which there are relatively few serious competitors.